Expertise

Patient Engagement

Growing patient involvement in Health Tech products development

Value-based healthcare is measured with direct patient outcomes largely developed by patient experts
Patients have unique experience and expertise in their disease
All along the drug and medical device development, patient experts and groups input is essential

Patient engagement

Direct participation of patient experts in the development of Health Tech products
Coherent co-construction of the clinical and regulatory strategy

3 levels of patient engagement

Patients are essential in your panel of experts

Patient engagement

Did you ever talk to patients to whom you aim to provide solutions?
Do you know their actual demand?
Do you know the healthcare pathways they follow, the difficulties to get a diagnosis?
Are you ready to invest in patient centricity?
Do you know that your products will be systematically evaluated by patient experts within regulatory agencies and HTA bodies?

Perform a health check to secure your development

We can help you:

Quantify the importance of patient groups in targeted indications and provide tips and solutions
Assist you in providing patient expertise in front of regulatory authorities and HTA bodies
Build a patient-centered value story to secure your positioning on the market
Strategy to integrate patient perspective in your development and selected access pathways

You may also be interested in our solutions for market access, regulatory and clinical trials and medical as they cannot be separated from your work with patient experts.

F.A.Q.

What’s the benefit of patient engagement?

Patients are no longer perceived as passive users of a treatment, but increasingly as active partners all along the healthcare product development process. The ultimate goal of patient engagement is to improve outcomes by taking the patient’s experience and voice into consideration. This can be achieved in various manners:

By integrating a full patient engagement strategy as early as possible, patients (and caregivers) can act as experts of their disease. They can provide essential information on the impact of the disease on their daily lives, the treatment journey, and their unmet needs. In addition, they can help to develop Patient Report Outcomes (PROs) that really matter to them along with potential barriers to treatment.
By collaborating with sponsors (and KOLs) in the development of the clinical protocol and patient information, it will lead to better patient enrolment, higher retention rates, resulting in higher quality data and cost savings.
By working collaboratively with patients, there are more chances to meet the regulatory agencies’ requirements and address the essential needs of the HTAs.
Finally, an ongoing, trusting and meaningful partnership with patient groups can be a powerful way to improve the dissemination of clinical results.

How and when to engage with the patient?

Patient engagement is a process that needs to start as early as possible in the product development plan, to obtain the unique insights only a patient can provide. This usually takes place during the critical Phase V and should be meaningful for all parties, built on mutual trust leading to a long-term relationship.

Patient engagement is not something you achieve overnight and can’t be improvised; it needs to be carefully planned and developed.

The selection of patient experts or groups is a critical step in your strategy, ensuring the expertise and assets match the needs of your specific program or project. Communication, partnership and feedback between the sponsor and the patient expert (patient organization) are key elements. Pharmaceutical companies benefit if they adopt a supportive approach with the strategic priorities placing patient involvement at the heart of the business.

What is the role of patient in a clinical trial?

Patients are no longer only passive patients receiving a drug candidate. They should be actively involved in the protocol design to ensure that clinical endpoints and outcomes answer their needs and preferences, optimizing trial’s recruitment and retention strategy by reducing as much as possible the burden linked to the trial’s participation. Documents for informed consent and trial material should ideally be co-produced with patients to ensure that all information is relevant, comprehensive and clearly understandable for patients, and that it is presented in a patient friendly language.

Patient Engagement

Growing patient involvement in Health Tech products development

Patient engagement

Patients are essential in your panel of experts

Perform a health check to secure your development

Incorporating patients’ voices in the drug development process

F.A.Q.

Expertise

Regulatory Strategy & Submissions

Access to Market

Clinical Research